Myeloid Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., August 29, 2024 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical-stage immunology company advancing RNA therapeutics to conquer cancer, announced today its participation in the following investor conferences:
- 22nd Annual Morgan Stanley Healthcare Conference, September 4-6, 2024, in New York, NY
- Wells Fargo Annual Healthcare Conference, September 4-6, 2024, in Boston, MA
- Chardan’s 3rd Annual SPICI Symposium, September 8-10, 2024, in San Diego, CA
- 4th Annual Needham Private Biotech Company Virtual 1×1 Forum, October 8-9, 2024
During these events, Company management will participate in one-on-one meetings with investors.
About Myeloid Therapeutics
Myeloid Therapeutics is a clinical stage immunology company, engineering cutting-edge RNA technology to program immune cells to combat cancer and other deadly diseases. Myeloid is headquartered in Cambridge, MA.
For additional information, please visit https://myeloidtx.com/ and follow us on LinkedIn and X/Twitter. For collaborative interests, write to [email protected].
Investor and Media Contact
Amy Conrad
Juniper Point
[email protected]